Národní monitorovací
středisko pro drogy
a závislosti

National Survey on Substance Use in the Czech Republic in 2016:

Parallel F2F and CAWI Data Collection and Differences in Results

Pavla Chomynová

7 June 2017| GPS expert meeting, EMCDDA, Lisbon

National Survey 2016

aim

monitor the situation in substance use in the general population

topic

smoking, alcohol, psychoactive medicines, illicit drugs, Internet use, gaming and gambling

mental health, risk sexual behaviour

age 15+

randomly selected respondents in households, face-to-face interviews (F2F)

+

complemented by on-line data collection (CAWI), randomly selected respondents from an Internet panel

monitoring of the situation

trends between 2008-2012-2016

compare the situation in Europe

estimates of the population at risk

National Survey 2016: Methodology

previous surveys in 2008 and 2012:

- multi-stage random sampling based on selection of cities and municipalities
- random route to select households, randomly selected respondents in households
- face-to-face interviews

2016 survey?

keep the methodology of F2F?

- random selection ensures representativeness
- non-response can be monitored
- comparability with previous surveys (2008 and 2012)
- BUT expensive and time consuming

change to CAWI?

- catches respondents not at home when the interviewer rings
- enables respondents to fill in the questionnaire on-line in their „free time", increases response rate
- BUT no previous experience/pilot

National Survey 2016: Methodology

+ NMC: received offers from agencies for research among on-line panels of respondents

Taking into account and balancing between:

response rate

sample size

price

Is there a difference between F2F and CAWI?

If not, it would make surveys much cheaper!

2 parallel parts

face-to-face interviews (F2F)

on-line survey – internet panel (CAWI)

4

National Survey 2016:
1. face-to-face interviews (F2F)

Multi-stage stratified random sampling

750 starting points

- **1 – cities and municipalities**
- strata (region x size)

476 municipalities

- **2 – starting points**

- **3 - households**
- random route
- 5th house, 5th flat

max. 10 interviews/address

1 resp/household, 15+

- **4 - respondent**
- nearest birthday

> double data entry, logic control
> weights for age groups 15+ a 15-64 years

National Survey 2016:
1. face-to-face interviews (F2F)

- altogether 283 interviewers

- up to 3 visits in selected households – different time

- address list – reporting reasons for refusal

Households contacted	**6 235**	
out of them:		
NI=no-one present	803	12.9%
CI=refusal when household first contacted	1 346	21.6%
CO=target person contacted but refused	410	6.6%
CN=target person not reached	49	0.8%
PR=interview started but not finished	28	0.4%
KR=completed interviews	**3 601**	**57.8%**

National Survey 2016: 2. on-line survey (CAWI)

Complex (combined) sampling using strata and quota

panel of Internet users registered

over 30 thous. persons

strata

age, gender, education, region, size of the place of residence

defined number of respondents

select

systematic key

email

link to the website with the questionnaire

> data automatically recorded into a database, logic control
> weights for age groups 15+ a 15-64 years (applied later)

National Survey 2016:
2. on-line survey (CAWI)

if no response, respondent substituted by another person fulfilling the same quota parameters

reminder

invitation letter by email – topic and time of data collection

Households contacted	6 974	
out of them:		
NR=no reaction, substituted	5 701	81.7%
Q=discarded (unfinished) questionnaires	65	0.9%
OS=oversampling (overfilled quota)	208	3.0%
KR=completed questionnaires	1 000	14.3%

Example: psychoactive medicines

SEDATIVES AND HYPNOTICS

1. In the last 12 months, have you used any tranquillizers (sedatives or anxiolytics) or medicines against insomnia (hypnotics)?

FOR INTERVIEWERS: SHOW <u>CARD</u> WITH A LIST OF MEDICINES. WE DO NOT ASK FOR OPIATES/OPIOIDS (USED MOSTLY AS PAINKILLERS) – THESE ARE SURVEYED IN QUESTIONS NO. **8–14.**

1☐	yes, once	
2☐	yes, more than once	
3☐	no	→ if not, continue with question no. 8

2. If yes, what kind of medicine it was?

FOR INTERVIEWERS: WRITE DOWN THE NAME OF GIVEN MEDICINE(S).

....

3. In the last 12 months, how often have you used tranquillizers or hypnotics?

1☐	every day or almost every day (5–7 times a week)
2☐	several times a week (3–4 times a week)
3☐	once or twice a week
4☐	several times a month (2–3 times a month)
5☐	once a month
6☐	less often than once a month

4. Have you used tranquillizers or hypnotics in the last 30 days?

1☐	yes	
2☐	no	→ if not, continue with question no. 6

National Survey 2016: Topics

1. tobacco smoking,

2. e-cigarettes,

3. alcohol use and
   regular consumption,

4. psychoactive medicines,

5. illicit drugs,

6. Internet use,

7. gaming and gambling,

mental health, life
satisfaction scale, risk
sexual behaviour

10

National Survey 2016: Tobacco Smoking

F2F (n=2875)

	Males	Females	Total 15-64	15-34
Lifetime	70,6	52,9	**61,4**	63,3
Last 30D	39,7	22,4	**30,7**	31,8
Daily smoking	35,6	18,3	**26,6**	26,2

CAWI (n=795)

	Males	Females	Total 15-64	15-34
Lifetime	85,5	80,5	**83,0**	83,9
Last 30D	26,1	22,6	**24,4**	19,4
Daily smoking	21,4	18,8	**20,1**	16,8

increase in daily smoking between 2012 a 2016:

males   45-54 years

Daily smoking by age

- **Males** — 35.6% / 21.4%
- **Females** — 18.3% / 18.8%
- **Total** — 26.6% / 20.1%
- **15-24** — 22.3% / 9.4%
- **25-34** — 28.8% / 26.1%
- **35-44** — 25.7% / 14.0%
- **45-54** — 30.8% / 27.7%
- **55-64** — 24.4% / 25.5%

■ F2F   ■ CAWI

National Survey 2016: Electronic Cigarette

F2F (n=2875)

	Males	Females	Total **15-64**	15-34
Lifetime	23,0	15,8	**19,2**	27,7
Last 12M	9,9	6,1	**7,9**	13,3
Last 30D	3,2	2,0	**2,6**	4,2

CAWI (n=795)

	Males	Females	Total **15-64**	15-34
Lifetime	38,9	43,2	**41,0**	43,8
Last 12M	19,0	18,5	**18,7**	24,7
Last 30D	13,1	12,6	**12,8**	15,8

lifetime prevalence of EC 2012: 18,3%

Electronic cigarette use in last 12 months

Males 9.9% 19.0%
Females 6.1% 18.5%
Total 7.9% 18.7%

15-24 17.1% 30.0%
25-34 10.4% 17.9%
35-44 5.8% 18.7%
45-54 4.8% 10.7%
55-64 4.2% 15.6%

F2F CAWI

Among those who used electronic cigarette in last 30 days (F2F)

8%
36%
36%
7%
13%

- Only EC
- Mostly EC but tobacco as well
- EC and tobacco about the same
- Mostly tobacco, sometimes EC
- Tobacco only

12

National Survey 2016: Alcohol Use

F2F (n=2875)

	Males	Females	Total **15-64**	15-34
Last 12M	88,5	76,4	**82,3**	79,8
Last 30D	81,4	61,5	**71,1**	68,8
Binge (5+ drinks every week)	19,9	6,6	**13,0**	12,5

CAWI (n=795)

	Males	Females	Total **15-64**	15-34
Last 12M	93,8	95,1	**94,5**	93,
Last 30D	87,9	81,0	**84,5**	84,2
Binge (5+ drinks every week)	18,5	6,7	**12,7**	9,2

Binge drinking (5+ glasses) every week

- 15-24: 2012 = 11.3, F2F 2016 = 7.4, CAWI 2016 = 5.9
- 25-34: 2012 = 13.2, F2F 2016 = 15.9, CAWI 2016 = 12.7
- 35-44: 2012 = 17.6, F2F 2016 = 12.4, CAWI 2016 = 15.1
- 45-54: 2012 = 12.5, F2F 2016 = 15.8, CAWI 2016 = 18.9
- 55-64: 2012 = 9.6, F2F 2016 = 11.8, CAWI 2016 = 10.6

■ 2012 ■ F2F 2016 ■ CAWI 2016

12,9 % in 2012, **13,0 %** in 2016 (F2F) and **12,7 %** (CAWI)

↓ 15-24   ↑ 45-54, 55-64

Binge drinking (5+ glasses) daily or almost daily

- 15-24: F2F = 0.0, CAWI = 0.9
- 25-34: F2F = 0.9, CAWI = 1.5
- 35-44: F2F = 1.0, CAWI = 1.7
- 45-54: F2F = 1.8, CAWI = 3.1
- 55-64: F2F = 1.8, CAWI = 0.6

■ F2F ■ CAWI

2,3 % in 2012, **1,3 %** in 2016 (F2F) and **1,5 %** (CAWI)

13

National Survey 2016: Psychoactive Medicines

F2F (n=2875)

Last 12 months	Males	Females	Total 15-64	15-34
Tranquillizers	6,0	13,5	**9,9**	5,3
Opioid analgesics	6,1	10,1	**8,1**	7,3
Psychoactive medicines	11,9	22,3	**17,3**	12,3

CAWI (n=795)

Last 12 months	Males	Females	Total 15-64	15-34
Tranquillizers	10,1	16,7	**13,3**	12,5
Opioid analgesics	8,6	10,6	**9,6**	4,9
Psychoactive medicines	15,3	24,2	**19,6**	15,4

higher among females

+in older age groups

Use of psychoactive medicines by age

	15-24	25-34	35-44	45-54	55-64
F2F	10.2%	14.0%	16.4%	22.4%	22.3%
CAWI	16.0%	14.8%	12.2%	21.4%	33.8%

■ F2F   ■ CAWI

National Survey 2016: Cannabis

F2F (n=2875)

	Males	Females	Total **15-64**	15-34
Lifetime	34,6	19,1	**26,6**	43,8
Last 12M	14,2	5,0	**9,5**	19,4
Last 30D	8,9	2,2	**5,5**	11,1

CAWI (n=795)

	Males	Females	Total **15-64**	15-34
Lifetime	39,8	35,2	**37,5**	51,6
Last 12M	11,1	9,5	**10,3**	18,1
Last 30D	6,2	3,3	**4,8**	9,2

Cannabis use in last 12 months by age

in 2012:

27,9 % lifetime
9,2 % last 12 M
4,4 % last 30D

F2F: same in 15-24 and 25-34
CAWI: decrease with age

- 15-24: 19.5% / 22.9%
- 25-34: 19.1% / 11.9%
- 35-44: 5.9% / 9.3%
- 45-54: 3.5% / 4.4%
- 55-64: 1.9% / 3.1%

■ F2F ■ CAWI

National Survey 2016: Cannabis

Among cannabis users in the last 12 months:

F2F   25,8% once

74,2% more than once

CAWI   51,2% once

48,8% more than once

Frequency of cannabis use among last-year users

31,8% every week }

31,1% every month }

37,1% less often }

higher frequency among F2F

F2F
- 2.3
- 8.7
- 20.8
- 22.0
- 9.1
- 37.1

CAWI
- 2.4
- 6.1
- 17.1
- 8.5
- 1.2
- 64.6

Legend:
- Daily or almost daily
- 3-4 times a week
- 1-2 times a week
- 2-3 times a month
- Once a month
- Less often

National Survey 2016: Medical Use of Cannabis

F2F (n=2875)

	Males	Females	Total 15-64	15-34
Lifetime	10,3	16,5	**13,5**	10,9
Last 12M	6,2	10,1	**8,2**	6,8

16,5% in 2012

CAWI (n=795)

	Males	Females	Total 15-64	15-34
Lifetime	23,4	33,4	**28,3**	26,7
Last 12M	14,3	19,0	**16,6**	14,1

Non-medical and medical use of cannabis 12M (F2F)

9,5% as a drug

8,2% medical use

Medical use of cannabis in lifetime

Age	F2F	CAWI
15-24	8.1%	31.8%
25-34	13.0%	20.7%
35-44	14.2%	27.5%
45-54	15.7%	34.0%
55-64	15.2%	26.3%

■ F2F ■ CAWI

	Cannabis use (12M)	Medical cannabis (12M)
Males	14.2%	6.2%
Females	5.0%	10.1%
Total	9.5%	8.2%
15-24	19.5%	5.3%
25-34	19.1%	8.0%
35-44	5.9%	8.3%
45-54	3.5%	9.5%
55-64	1.9%	9.2%

■ Cannabis use (12M) ■ Medical cannabis (12M)

National Survey 2016: Illicit Drugs (Lifetime Prevalence)

F2F (n=2875)

	Males	Females	Total **15-64**	15-34
Ecstasy	10,0	4,4	**7,1**	14,3
Pervitin (methamphetamine)	4,5	1,5	**3,0**	5,9
Cocaine	2,2	0,6	**1,4**	2,4
Heroin	1,2	0,3	**0,7**	1,3
LSD	3,3	1,1	**2,1**	3,6
Hallucinogenic mushrooms	8,0	3,0	**5,4**	10,3
New psychoactive substances	0,9	0,4	**0,7**	1,2
Anabolic steroids	7,1	1,1	**4,0**	5,6
Inhalants	6,1	1,8	**3,9**	4,7

CAWI (n=795)

	Males	Females	Total **15-64**	15-34
Ecstasy	4,4	5,7	**5,0**	7,9
Pervitin (methamphetamine)	3,4	4,9	**4,2**	5,9
Cocaine	4,2	3,1	**3,6**	7,2
Heroin	0,7	0,3	**0,5**	0,0
LSD	4,9	3,1	**4,0**	6,2
Hallucinogenic mushrooms	7,9	3,1	**5,5**	9,2
New psychoactive substances	3,4	1,0	**2,3**	4,9
Anabolic steroids	3,4	0,3	**1,9**	2,6
Inhalants	8,9	1,5	**5,3**	9,5

National Survey 2016: Illicit Drugs

Lifetime prevalence of illicit substances

Substance	F2F	CAWI
Ecstasy	7.1	5.0
Pervitin	3.0	4.2
Cocaine	1.4	3.6
Heroin	0.7	0.5
LSD	2.1	4.0
Hallucinogenic mushrooms	5.4	5.5
New psychoactive substances	0.7	2.3
Inhalants	3.9	1.9
Anabolic steroids	4.0	5.3

F2F CAWI

F2F
Ecstasy
inhalants

CAWI
pervitin
cocaine
LSD
anabolic steroids

↑ Ecstasy and pervitin use higher among females (in CAWI)

↑ use of all substances higher in younger age groups (15-34)

same pattern for the last 12 months prevalence

Ecstasy

Age	F2F	CAWI
15-24	14.6%	5.9%
25-34	14.0%	9.7%
35-44	5.5%	7.6%
45-54	2.6%	1.9%
55-64	0.9%	0.6%

Pervitin

Age	F2F	CAWI
15-24	4.6%	4.7%
25-34	6.8%	7.5%
35-44	1.7%	5.3%
45-54	1.8%	3.1%
55-64	0.5%	0.0%

Cocaine

Age	F2F	CAWI
15-24	1.6%	7.1%
25-34	3.1%	7.4%
35-44	1.2%	1.7%
45-54	1.2%	2.5%
55-64	0.0%	0.0%

LSD

| Age	F2F	CAWI
15-24	3.9%	4.7%
25-34	3.6%	7.5%
35-44	2.2%	6.4%
45-54	0.9%	1.3%
55-64	0.5%	0.6%

in F2F highest prevalence among 25-34, followed by 15-24

in CAWI highest prevalence among 25-34 followed by 35-44

National Survey 2016: Any Illicit Drug Including Cannabis by Age

*Lifetime prevalence of any illicit drug including cannabis*

Age	F2F	CAWI
15-24	44.5%	45.6%
25-34	51.9%	63.7%
35-44	30.3%	42.7%
45-54	19.5%	29.1%
55-64	8.5%	15.0%

■ F2F   ■ CAWI

Last 12 months prevalence of any illicit drug including cannabis

Age	F2F	CAWI
15-24	23.4%	24.3%
25-34	21.7%	18.5%
35-44	7.9%	11.0%
45-54	5.3%	4.4%
55-64	2.3%	3.1%

■ F2F   ■ CAWI

Summary

National Survey on Substance Use 2016:

face-to-face interviews (F2F)

on-line survey – internet panel (CAWI)

→ **Is there a difference between F2F and CAWI?**

Findings:

differences in prevalences

lifetime prevalence of substance use
Internet use, Social Media, on-line gaming and gambling for money, risk (sexual) behaviour

more consistent as regards current use and more intensive forms of use (daily smoking, binge drinking)

different population???

- o higher education – weights applied later;
- o lower response rate (14.3%) – but those responding were „interested" in the topic and willing to report more openly on their substance use and risk behaviour;
- o „pre-selected" – access to Internet, willing to participate in surveys, experienced.

Conclusion

Is there a difference between F2F and CAWI?

Yes, there is.

No shift to on-line surveys in Internet samples.
Keep traditional ways of F2F interviews.
No money saving

Budget for F2F part = 884 thousand CZK

= 33 500 €, i.e. 9,60 € per respondent

Budget for CAWI part = 84 thousand CZK

= 3 180 €, i.e. 3,20 € per respondent

1/3 of the costs of F2F

in 2016 = budget for sampling, training of interviewers, questionnaire printing, field data collection and (double) data entry

Národní monitorovací středisko pro drogy a závislosti

Thank you

Pavla Chomynova

Czech National Monitoring Centre for Drugs and Addictions

chomynova.pavla@vlada.cz

www.drogy-info.cz
rvkpp.vlada.cz
www.vlada.cz
www.hazardni-hrani.cz

National website for support of smoking cessation:
www.koureni-zabiji.cz
National hotline for smoking cessation: 800 35 00 00

Overview of Surveys in the Czech Republic Between 2008–2016

Survey	2008	2009	2010	2011	2012	2013	2014	2015	2016
European Health Interview Survey (EHIS)	N=1955 Age 15+ F2F, PAPI Resp.=50%						N=6737 Age 15+ F2F, PAPI Resp.=70%		
GPS on Substance Use and Attitudes Towards Substance Use in the CR	**N=4506 Age 15-64 F2F, PAPI Resp.=80,3%**								
Survey on Opinions and Attitudes of the Citizens of the CR Towards Health Care and Healthy Lifestyle		N=1795 Age 15+ F2F, PAPI	N=1487 Age 15+ F2F, PAPI		N=1802 Age 15+ F2F, PAPI	N=1797 Age 15+ F2F, PAPI	N=1810 Age 15+ F2F, PAPI	N=1798 Age 15+ F2F, PAPI	N=1841 Age 15+ F2F, PAPI
Prevalence of Drug Use in the Population of the CR				N=1028 Age 15+ F2F, CAPI	N=976 Age 15+ F2F, CAPI	N=1005 Age 15+ F2F, CAPI	N=1005 Age 15+ F2F, CAPI	N=1050 Age 15+ F2F, CAPI	N=1040 Age 15+ F2F, CAPI
National Survey on Substance Use					**N=2134 Age 15-64 F2F, PAPI Resp.=62%**				**N=4601 Age 15+ F2F (PAPI) + CAWI Resp.=57,8%**